- Home
- ACXP vs LSTA Comparison
ACXP vs LSTA Comparison
Compare ACXP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- LSTA
- Stock Information
- Founded
- ACXP 2017
- LSTA 1980
- Country
- ACXP United States
- LSTA United States
- Employees
- ACXP N/A
- LSTA N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- ACXP Health Care
- LSTA Health Care
- Exchange
- ACXP Nasdaq
- LSTA Nasdaq
- Market Cap
- ACXP 8.4M
- LSTA 24.1M
- IPO Year
- ACXP 2021
- LSTA N/A
- Fundamental
- Price
- ACXP $0.49
- LSTA $2.61
- Analyst Decision
- ACXP Strong Buy
- LSTA Strong Buy
- Analyst Count
- ACXP 2
- LSTA 1
- Target Price
- ACXP $10.00
- LSTA $15.00
- AVG Volume (30 Days)
- ACXP 18.6M
- LSTA 15.8K
- Earning Date
- ACXP 08-08-2025
- LSTA 08-11-2025
- Dividend Yield
- ACXP N/A
- LSTA N/A
- EPS Growth
- ACXP N/A
- LSTA N/A
- EPS
- ACXP N/A
- LSTA N/A
- Revenue
- ACXP N/A
- LSTA $1,000,000.00
- Revenue This Year
- ACXP N/A
- LSTA N/A
- Revenue Next Year
- ACXP N/A
- LSTA N/A
- P/E Ratio
- ACXP N/A
- LSTA N/A
- Revenue Growth
- ACXP N/A
- LSTA N/A
- 52 Week Low
- ACXP $0.30
- LSTA $1.87
- 52 Week High
- ACXP $3.33
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- ACXP 51.01
- LSTA 50.61
- Support Level
- ACXP $0.46
- LSTA $2.36
- Resistance Level
- ACXP $0.56
- LSTA $3.07
- Average True Range (ATR)
- ACXP 0.10
- LSTA 0.23
- MACD
- ACXP -0.01
- LSTA 0.02
- Stochastic Oscillator
- ACXP 24.27
- LSTA 37.50
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.